Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 4/20 | 1.00 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 5/20 | 0.36 |
| ▸ | MMP13 | P45452 | 5/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | PTPRZ1 | P23471 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | KCNK2 | O95069 | 2/20 | 0.34 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3930274 | 0.89 | CXCR2 (0.80) | CXCR2CXCR5CYP4F2CYP4A11MMP1 | |
| SCHEMBL15911883 | 0.88 | CXCR2 (0.79) | CXCR2MMP1MMP13MMP2MMP3 | |
| SCHEMBL485624 | 0.84 | CXCR2 (0.72) | CXCR2CXCR5PTPRZ1PPARGPPARD | |
| SCHEMBL485489 | 0.84 | CXCR2 (0.72) | CXCR2CXCR5PTPRZ1PPARGPPARD | |
| SCHEMBL485166 | 0.81 | CXCR2 (0.69) | CXCR2CXCR5PPARDPPARAPTPN1 | |
| SCHEMBL485250 | 0.80 | CXCR2 (0.67) | CXCR2CXCR5PTPRZ1KCNK2KCNK10 | |
| SCHEMBL485653 | 0.80 | CXCR2 (0.67) | CXCR2CXCR5PTPRZ1PPARGPPARD | |
| SCHEMBL484994 | 0.79 | CXCR2 (0.65) | CXCR2PTPRZ1PPARGPPARDPPARA | |
| SCHEMBL3924703 | 0.78 | CXCR2 (0.64) | CXCR2CXCR5PTPRZ1PPARGPPARD | |
| SCHEMBL485279 | 0.77 | CXCR2 (0.62) | CXCR2CXCR5CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040690-B1 | INHIBITORS OF CXCR2 | SANOFI SA (FR) | 2014-08-06 | — | — | EP | claimed |
| US-8552033-B2 | Inhibitors of CXCR2 | SANOFI (FR) | 2013-10-08 | — | — | US | claimed |
| US-20090215827-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | claimed |
| EP-2040690-B1 | INHIBITORS OF CXCR2 | SANOFI SA (FR) | 2014-08-06 | — | — | EP | disclosed |
| EP-2040690-B1 | INHIBITORS OF CXCR2 | SANOFI SA (FR) | 2014-08-06 | — | — | EP | disclosed |
| US-8552033-B2 | Inhibitors of CXCR2 | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-8552033-B2 | Inhibitors of CXCR2 | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-8552033-B2 | Inhibitors of CXCR2 | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-20090215827-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090215827-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090215827-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| EP-2040690-A1 | INHIBITORS OF CXCR2 | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008000407-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008000407-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215827-A1 | INHIBITORS OF CXCR2 | CXCR2, CXCR1, CXCR4 | CXCR2 1/4885CXCR5 5/4885CYP4F2 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.